US 12,433,860 B2
Treatment of multiple sclerosis comprising DHODH inhibitors
Andreas Mühler, Munich (DE); Hella Kohlhof, Munich (DE); and Daniel Vitt, Germering (DE)
Assigned to IMMUNIC AG, Gräfelfing (DE)
Filed by Immunic AG, Gräfelfing (DE)
Filed on Dec. 5, 2023, as Appl. No. 18/529,946.
Application 18/529,946 is a continuation of application No. 17/391,442, filed on Aug. 2, 2021, granted, now 11,877,994.
Prior Publication US 2024/0180858 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61K 9/00 (2006.01); A61K 31/136 (2006.01); A61K 31/137 (2006.01); A61K 31/225 (2006.01); A61K 31/397 (2006.01); A61K 31/4704 (2006.01); A61K 31/785 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 9/0053 (2013.01); A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/225 (2013.01); A61K 31/397 (2013.01); A61K 31/4704 (2013.01); A61K 31/785 (2013.01); A61K 38/215 (2013.01); A61K 39/3955 (2013.01); A61P 25/28 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating a human patient afflicted with progressive multiple sclerosis, the method comprising orally administering to the human patient at least one compound chosen from 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid a pharmaceutically acceptable salt or a solvate thereof, at a daily dose of about 10 mg to 45 mg of the at least one compound so as to alleviate a symptom of or a condition associated with progressive multiple sclerosis, thereby treating the human patient.